Roivant Sciences Ltd. (NASDAQ: ROIV) director-linked entity sells shares

Rhea-AI Filing Summary

Roivant Sciences Ltd. reported insider share sales linked to director Daniel Allen Gold. QVT Financial Investment Cayman Ltd., where Gold is one of three directors, executed a series of open-market sales of Roivant common shares on February 11–13, 2026 at prices between $26.49 and $26.76 per share.

Individual transactions ranged from 150,000 to 425,000 common shares, with the last reported sale at $26.50 per share. Following the final transaction, 15,127,329 common shares were indirectly held by QVT Financial Investment Cayman Ltd. Gold shares voting and investment control over these shares and disclaims beneficial ownership beyond his pecuniary interest.

Insider Trade Summary

Net Seller: 1,225,784 shares ($32,658,518)

Net Sell 5 txns

Insider Gold Daniel Allen

Role Director

Sold 1,225,784 shs ($32.66M)

Type	Security	Shares	Price	Value
Sale	Common Shares	150,784	$26.49	$3.99M
Sale	Common Shares	225,000	$26.50	$5.96M
Sale	Common Shares	150,000	$26.72	$4.01M
Sale	Common Shares	275,000	$26.76	$7.36M
Sale	Common Shares	425,000	$26.67	$11.33M

Holdings After Transaction: Common Shares — 15,352,329 shares (Indirect, Held by QVT Financial Investment Cayman Ltd.)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gold Daniel Allen

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON X0 SW1H 0DB

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/11/2026		S		425,000	D	$26.67	15,928,113	I(1)	Held by QVT Financial Investment Cayman Ltd.
Common Shares	02/12/2026		S		150,000	D	$26.72	15,778,113	I(1)	Held by QVT Financial Investment Cayman Ltd.
Common Shares	02/12/2026		S		275,000	D	$26.76	15,503,113	I(1)	Held by QVT Financial Investment Cayman Ltd.
Common Shares	02/13/2026		S		150,784	D	$26.49	15,352,329	I(1)	Held by QVT Financial Investment Cayman Ltd.
Common Shares	02/13/2026		S		225,000	D	$26.5	15,127,329	I(1)	Held by QVT Financial Investment Cayman Ltd.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person is one of three directors of QVT Financial Investment Cayman Ltd. ("QVT FIC"), sharing voting and investment control over the Common Shares held directly by QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.

	/s/ Dan Gold	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions in ROIV stock were reported in this Form 4?

The filing reports multiple open-market sales of Roivant Sciences common shares by QVT Financial Investment Cayman Ltd. between February 11 and 13, 2026, at prices from $26.49 to $26.76 per share, with individual trades of 150,000 to 425,000 shares.

Who is the reporting person in Roivant Sciences (ROIV) Form 4?

The reporting person is director Daniel Allen Gold. He is one of three directors of QVT Financial Investment Cayman Ltd., the entity that directly holds and sold the Roivant common shares disclosed, and he reports these indirect holdings subject to a pecuniary-interest disclaimer.

Which entity actually sold Roivant Sciences (ROIV) shares in this filing?

The sales were made by QVT Financial Investment Cayman Ltd., which directly holds the Roivant common shares. Daniel Allen Gold is one of three directors sharing voting and investment control over these shares, according to the footnote in the Form 4 filing.

What prices and sizes were the recent ROIV insider share sales?

Reported transactions include sales of 425,000, 275,000, 225,000, 150,784, and 150,000 Roivant common shares. Sale prices ranged from $26.49 to $26.76 per share in open-market transactions on February 11–13, 2026.

How many Roivant Sciences (ROIV) shares were indirectly held after the last sale?

After the final reported transaction on February 13, 2026, QVT Financial Investment Cayman Ltd. indirectly held 15,127,329 Roivant Sciences common shares. This figure reflects the position following the last disclosed open-market sale at $26.50 per share.

Does Daniel Allen Gold claim full beneficial ownership of the ROIV shares?

No. The footnote states Daniel Allen Gold disclaims beneficial ownership of the Roivant shares held by QVT Financial Investment Cayman Ltd., except to the extent of his pecuniary interest. He shares voting and investment control as one of three QVT FIC directors.